
The FDA has approved its first treatment for peanut allergy in patients between ages four and 17. The drug is …

US biopharmaceutical firm Aimmune has revealed that its peanut allergy candidate AR101 hit its primary endpoint in the largest trial …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

